Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Down 2.4%
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Down 2.4%
Shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) fell 2.4% during mid-day trading on Wednesday . The stock traded as low as $4.45 and last traded at $4.98. 7,351,853 shares traded hands during mid-day trading, an increase of 1,036% from the average session volume of 646,993 shares. The stock had previously closed at $5.10.
納斯達克股票代碼:QNRX-GET評級週三午盤下跌2.4%。該股一度跌至4.45美元,最後報4.98美元。午盤成交量為7,351,853股,較646,993股的平均成交量增加1,036%。該股此前收盤價為5.10美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Several brokerages recently issued reports on QNRX. LADENBURG THALM/SH SH began coverage on Quoin Pharmaceuticals in a research note on Friday, May 6th. They issued a "buy" rating and a $25.00 price target for the company. Maxim Group cut their price target on Quoin Pharmaceuticals to $25.00 in a research note on Thursday, May 26th.
幾家券商最近發佈了關於QNRX的報告。拉登堡THALM/SH SH在5月6日星期五的一份研究報告中開始報道Quoin PharmPharmticals。他們對該公司的評級為“買入”,目標價為25美元。Maxim Group在5月26日星期四的一份研究報告中將Quoin PharmPharmticals的目標價下調至25.00美元。
Quoin Pharmaceuticals Stock Performance
Quoin製藥類股表現
The firm has a 50 day simple moving average of $6.04 and a two-hundred day simple moving average of $11.38.
該公司的50日簡單移動均線切入位在6.04美元,200日簡單移動均線切入位在11.38美元。
Institutional Investors Weigh In On Quoin Pharmaceuticals
機構投資者看好Quoin製藥公司
An institutional investor recently bought a new position in Quoin Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,665 shares of the company's stock, valued at approximately $57,000. Virtu Financial LLC owned about 0.51% of Quoin Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 21.72% of the company's stock.
一家機構投資者最近買入了Quoin PharmPharmticals股票的新頭寸。根據Virtu Financial LLC最近提交給美國證券交易委員會的13F文件,該公司在第一季度購買了Quoin PharmPharmticals,Ltd.(納斯達克代碼:QNRX-GET Rating)的新股票頭寸。該機構投資者購買了42,665股該公司股票,價值約57,000美元。在最近的報告期結束時,Virtu Financial LLC擁有Quoin製藥公司約0.51%的股份。機構投資者持有該公司21.72%的股份。
Quoin Pharmaceuticals Company Profile
Quoin製藥公司簡介
(Get Rating)
(獲取評級)
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease.
Quoin PharmPharmticals,Ltd.是一家專業製藥公司,專注於開發治療罕見和孤兒疾病的產品。該公司的主導產品是QRX003,一種治療Netherton綜合徵的外用洗劑。它還開發了用於治療營養不良性大皰性表皮鬆解症的QRX004;以及治療罕見皮膚病的QRX006。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Quoin Pharmaceuticals (QNRX)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
- 免費獲取StockNews.com關於Quoin PharmPharmticals的研究報告(QNRX)
- 大型和小型石油和天然氣類股盈利後反彈
- 連續十年上漲的兩隻道指股票
- Rite Aid會再次成為收購目標嗎?
- 投資石油股票的方式和原因
- 投資黃金股票的方式和原因
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Quoin PharmPharmticals Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Quoin製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。